Nitin Jain, MD, explains the key takeaways from multiple discussions on acute lymphoblastic leukemia which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.
Nitin Jain, MD, associate professor in the department of leukemia, division of cancer medicine, at the University of Texas MD Anderson Cancer Center, explains the key takeaways from multiple discussions on acute lymphoblastic leukemia (ALL) which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.
During a session on the first day of the meeting, experts, including Jain, discussed different aspects of ALL, including pediatric data, minimal residual disease (MRD), and allogeneic chimeric antigen receptor (CAR) T cells within the space.
In the talk, Jain noted the evolving importance of allogeneic CAR T cells in ALL and how the future of this space aims to examine its efficacy compared with autologous CAR T.
Transcription:
0:08 | I think in the session this morning, we had 3 fantastic talks. One talked about the pediatric data and the younger data in ALL, another talk was on the MRD in ALL, and the third talk which I gave was in the allogeneic CAR T cells. Overall, I think it was good to see I think there are different aspects of things which are being developed. We learned the use that continues to be important for children and young adults. We learned that MRD techniques are being refined, and there are next generation sequencing technologies which are coming along more in the context of ALL.
0:45 | The talk which I gave about allogeneic CARs, is a space which is evolving, and we have to see how things pan out in the next 1 to 2 years. But I think if allogeneic CARs were to show equal efficacy to autologous CARs, that will be a game changer in terms of how we are approaching CAR T for these patients.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More